Pulmobiotics Highlights Nature Biotechnology Publication of Preclinical Data Demonstrating Clearance of Antibiotic-resistant Lung Infection
19 janv. 2023 11h39 HE
|
Pulmobiotics, S.L.
-- First ‘living medicine’ to treat antibiotic-resistant Pseudomonas aeruginosa infections in the lung, a leading cause of mortality in hospital settings – -- Data demonstrate treatment reduced lung...
Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)
19 janv. 2023 06h58 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that SYNB1934 was granted...
Telesis Bio Pre-Announces Preliminary Fourth Quarter Financial Results
09 janv. 2023 09h00 HE
|
Telesis Bio
-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21 -- Successful achievement of first technical milestone with Pfizer...
Landkind Announces Preliminary Results from ISTO Clinical Study Showing LK-01™ Pure Salidroside Supports Oxygen Uptake and Mood state
05 janv. 2023 09h00 HE
|
DoubleRainbow Biosciences
LEXINGTON, MASS., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landkind, a subsidiary of DoubleRainbow Biosciences leveraging advances in synthetic biology to deliver precision-engineered supplements to...
Synlogic Provides Corporate Update and Outlook for 2023
05 janv. 2023 06h58 HE
|
Synlogic, Inc.
Pivotal Phase 3 for SYNB1934 in phenylketonuria (PKU) to initiate in H1 2023 Rare Pediatric Disease Designation received for SYNB1353 for homocystinuria (HCU) Cash runway expected into H2 2024 ...
Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development
03 janv. 2023 06h58 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through...
Landkind reaches significant regulatory milestone, achieving GRAS status for LK-01™ Pure Salidroside
19 déc. 2022 08h00 HE
|
DoubleRainbow Biosciences
LEXINGTON, MASS., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Landkind, a subsidiary of DoubleRainbow Biosciences leveraging advances in synthetic biology to deliver precision-engineered supplements to...
Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study
15 déc. 2022 06h59 HE
|
Synlogic, Inc.
Results include -38% reduction in urinary oxalate compared to placebo in Roux-en-Y gastric bypass patients Favorable safety and tolerability, with frequency and severity of adverse events similar...
Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update
30 nov. 2022 16h15 HE
|
Synlogic, Inc.
Top-line Phase 1 data in healthy volunteers show that SYNB1353 reduces plasma methionine by consuming methionine in the GI tract SYNB1353 has been granted Orphan Drug Designation (ODD) from the FDA...
Double Rainbow Announces World’s First Commercial-Scale Biosynthetic Gastrodin, a Natural Analgesic with a Range of Therapeutic Applications
28 nov. 2022 09h41 HE
|
DoubleRainbow Biosciences
Lexington, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- DoubleRainbow Biosciences (“Double Rainbow”), a sustainable biotech company harnessing bioengineering to improve the quality of human health,...